MOVEMENT DISORDER CLINIC · NEURO ACTIVE · TOPIC: PARKINSON'S DISEASE · REF: MDS / AAN / FDA

The Basal Ganglia Atlas Movement disorder reference · U.S. edition

Neurology · Neurodegenerative

Parkinson's disease begins in the substantia nigra — years before the first tremor.

An estimated one million Americans live with Parkinson's disease, and by the time the classic motor symptoms appear, more than half of the dopamine-producing neurons in a small midbrain region have already been lost. This is the practical map: what degenerates, what the symptoms mean, how staging works, and how modern therapy manages the disease over decades.

14 min read

MDS/AAN-aligned

TRAP · H&Y · UPDRS

1M+

Americans live with Parkinson's disease — and about 90,000 new cases are diagnosed each year.

60%

Of dopamine neurons in the substantia nigra are already lost when the first motor symptoms appear.

Prevalence in adults over 80 — age is the strongest single risk factor.

10–20

Years typical duration from diagnosis to advanced disease — highly variable between patients.

Section 01 · The mechanism

Dopamine loss in the substantia nigra — and the circuit imbalance it creates.

Parkinson's disease is a progressive neurodegenerative disorder defined by the loss of dopamine-producing neurons in the substantia nigra pars compacta (SNc) — a small pigmented region in the midbrain that projects to the striatum. These neurons are part of the basal ganglia circuit, a group of deep brain structures that select and scale movement. When they die, the circuit loses its ability to modulate motor output — and the classical symptoms emerge.

The basal ganglia work through two parallel pathways that have opposing effects. The direct pathway (D1 receptors) facilitates movement by releasing the thalamus from inhibition, letting the cortex activate motor programs. The indirect pathway (D2 receptors) suppresses unwanted movement by increasing inhibition of the thalamus. In a healthy brain, dopamine keeps these pathways balanced. In Parkinson's, dopamine loss causes the indirect pathway to become overactive and the direct pathway underactive — the net result being excessive inhibition of the thalamus, and therefore reduced cortical activation of movement. That is what bradykinesia (slowness) represents at the circuit level.

What kills the neurons is incompletely understood. The pathological hallmark is the Lewy body — an intracellular aggregate composed primarily of misfolded α-synuclein protein. Lewy bodies appear in the SNc and other brain regions years before motor symptoms emerge, and their spread through the nervous system correlates with the progression of symptoms. This is why Parkinson's is now understood as a multisystem disease — motor symptoms are the tip of a much larger iceberg that includes the gut, the olfactory system, and the autonomic nervous system.

Genetic and environmental contributions. About 10 to 15 percent of cases have a clear genetic component — mutations in LRRK2, GBA, SNCA, PRKN, and other genes have been identified. The most common genetic risk factor is a GBA mutation, found in 5 to 10 percent of patients. Environmental factors — pesticide exposure, prior head injury, and possibly certain infections — also contribute. Most cases are considered sporadic, meaning no single cause is identifiable.

Section 02 · Motor symptoms

TRAP — the four cardinal features of Parkinson's disease.

Not every patient has all four, and the pattern varies. Diagnosis requires bradykinesia plus at least one of the other three — rigidity, rest tremor, or postural instability.

Tremor — rest tremor

The classic "pill-rolling" tremor at 4 to 6 Hz, present at rest and reduced with voluntary movement. Starts asymmetrically — one hand or one leg first. Not everyone with Parkinson's has tremor, and tremor alone without bradykinesia is not diagnostic.

Rigidity — lead-pipe & cogwheel

Increased resistance to passive movement, felt as constant ("lead-pipe") or ratchety ("cogwheel") resistance. Contributes to the masked face, stooped posture, and reduced arm swing on the affected side. Often noticed by the patient's family before the patient.

Akinesia & bradykinesia

Slowness of movement and difficulty initiating it. The most disabling motor symptom and the one most responsive to levodopa. Shows up as reduced handwriting (micrographia), shortened stride, softer voice (hypophonia), and difficulty with fine motor tasks.

Postural instability — late

Impaired balance and righting reflexes. Usually a late feature — if present at diagnosis, consider atypical parkinsonism. Responds poorly to levodopa and is a major contributor to falls and disability in advanced disease.

Non-motor symptoms are common and often predate motor symptoms by years. These include loss of smell (anosmia), REM sleep behavior disorder, chronic constipation, depression and anxiety, orthostatic hypotension, urinary urgency, and cognitive changes. Some of these — particularly anosmia and REM sleep behavior disorder — appear a decade or more before the first motor symptom and represent the earliest stages of the disease. Recognizing them can open the door to earlier diagnosis and, potentially, earlier intervention as disease-modifying therapies emerge.

What Parkinson's is not. It is not a normal part of aging, and it is not the same as essential tremor (which is a separate condition with a different mechanism and a different treatment). It is also distinct from atypical parkinsonian syndromes such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration — these look similar but progress faster and respond poorly to levodopa. Distinguishing them requires a neurologist and, sometimes, specialized imaging.

Section 03 · Staging

Hoehn & Yahr — the clinical scale that describes progression.

Several scales describe Parkinson's severity. The Hoehn and Yahr scale is the simplest and most widely used for clinical communication; the MDS-UPDRS is more detailed and used in research and specialized clinics.

Hoehn & Yahr · Modified

Clinical staging of Parkinson's disease

Stage	Clinical description	Functional implications
Stage 1	Unilateral symptoms only	Mild symptoms, often misattributed to injury or stress. Usually no functional impairment, no balance problems.
Stage 2	Bilateral symptoms, no balance impairment	Both sides affected but posture intact. Symptoms interfere with daily activities but patient remains independent.
Stage 3	Bilateral symptoms + postural instability	Balance impairment becomes apparent. Physical independence still possible but falls risk increases. Major milestone in progression.
Stage 4	Severe disability, still able to walk or stand unassisted	Significant functional limitation. Requires assistance with many activities of daily living. Motor fluctuations and dyskinesia common.
Stage 5	Wheelchair-bound or bedridden	Cannot stand or walk without assistance. Requires full-time care. Usually associated with advanced disease and complications.

Beyond staging. Progression is not linear, and patients can spend years in a single stage. Non-motor symptoms often dominate quality of life in advanced disease — particularly cognitive impairment, autonomic dysfunction, and sleep disruption. The MDS-UPDRS provides a more granular assessment across four parts: motor experiences of daily living, motor examination, non-motor experiences, and motor complications. It is the standard outcome measure for clinical trials and is increasingly used in specialty clinics to guide therapy.

Section 04 · Pharmacotherapy

Five drug classes — and how they work together.

Parkinson's medications all aim to restore dopamine signaling in the striatum, either directly or by modulating the pathways that synthesize or break down dopamine. The choice and combination depend on symptom severity, age, cognitive status, and side effect tolerance.

GOLD STANDARD · DA PRECURSOR

Levodopa / carbidopa

The most effective medication for motor symptoms, and the standard first-line for most patients. Levodopa crosses the blood-brain barrier and is converted to dopamine by surviving neurons. Carbidopa prevents peripheral conversion, reducing nausea and increasing brain delivery.

Available as immediate-release, extended-release, and orally disintegrating tablets. Long-term use is associated with motor fluctuations and dyskinesia, which are managed with dosing changes and adjunctive medications.

carbidopa/levodopa (Sinemet, Rytary, Duopa) · carbidopa/levodopa ER

DIRECT AGONISTS

Dopamine agonists

Directly stimulate dopamine receptors in the striatum — do not require conversion. Longer duration of action than levodopa and less associated with dyskinesia, but more likely to cause impulse control disorders (compulsive gambling, shopping, hypersexuality), daytime sleepiness, and leg edema.

Often used in younger patients as initial monotherapy, or added to levodopa as the disease progresses. Require tapering — abrupt discontinuation can cause a dangerous withdrawal syndrome.

pramipexole · ropinirole · rotigotine (patch) · apomorphine (rescue)

MAO-B INHIBITORS

MAO-B inhibitors

Block the enzyme monoamine oxidase B, which breaks down dopamine in the brain. Modest symptomatic benefit and a favorable side effect profile. Often used early in the disease or as an adjunct to levodopa to reduce "off" time.

Do not combine with certain antidepressants (risk of serotonin syndrome) or with meperidine. Rasagiline and selegiline are the two main agents.

rasagiline · selegiline · safinamide

COMT INHIBITORS

COMT inhibitors

Block catechol-O-methyltransferase, another enzyme that breaks down levodopa. Extends the effect of each levodopa dose — particularly useful for patients with wearing-off. Available as a tablet or as an add-on to levodopa/carbidopa formulations.

Can worsen dyskinesia and cause diarrhea (more common with tolcapone). Tolcapone carries a boxed warning for liver toxicity and requires periodic liver enzyme monitoring.

entacapone · opicapone · tolcapone (with monitoring)

OTHER ADJUNCTS

Amantadine & anticholinergics

Amantadine has mild antiparkinsonian effects and is the primary medication for levodopa-induced dyskinesia. Originally developed as an antiviral, its mechanism in Parkinson's is not fully understood.

Anticholinergics (trihexyphenidyl, benztropine) are used mainly in younger patients with prominent tremor. They are avoided in older adults because of cognitive side effects, confusion, and urinary retention.

amantadine · trihexyphenidyl · benztropine

Section 05 · Motor fluctuations

"On" and "off" — the phenomenon that defines advanced Parkinson's care.

After several years of levodopa therapy, the brain's ability to buffer dopamine fluctuations declines. Doses that once worked smoothly begin to wear off between scheduled times, and the clinical picture becomes divided into "on" and "off" states.

"On" periods — medication working

Symptoms controlled · functional

Movement is easier, tremor and rigidity reduced.
Duration shortens as disease progresses — from hours to minutes between doses.
Can be associated with peak-dose dyskinesia — involuntary writhing movements that are often more bothersome than the "off" state itself.
Managing dyskinesia is a major focus of advanced therapy adjustments.

OFF

"Off" periods — medication wearing off

Symptoms return · function impaired

Return of tremor, rigidity, slowness, and often anxiety.
Can be predictable (wearing off) or unpredictable (sudden off) — the latter is particularly disabling.
Non-motor "off" symptoms include pain, sweating, mood changes, and difficulty speaking.
May be improved by dose frequency adjustments, COMT inhibitors, MAO-B inhibitors, or device-assisted therapies.

Section 06 · Advanced therapies

When medications are no longer enough — device-assisted options.

Deep brain stimulation (DBS) is the most established surgical therapy for advanced Parkinson's. Electrodes are implanted in the subthalamic nucleus (STN) or globus pallidus interna (GPi) and connected to a pulse generator implanted under the skin of the chest. DBS does not cure Parkinson's and does not slow progression — but it can dramatically reduce motor fluctuations, dyskinesia, and tremor, and improve quality of life in appropriately selected patients. The ideal candidate is a patient with idiopathic Parkinson's, levodopa-responsive symptoms, troublesome fluctuations or dyskinesia, no significant cognitive impairment, and realistic expectations. Programming requires multiple visits, and stimulation parameters are adjusted over time.

Levodopa-carbidopa intestinal gel (LCIG, Duopa) delivers levodopa continuously through a percutaneous endoscopic gastrostomy (PEG) tube into the small intestine. This bypasses the variability of gastric emptying and produces steadier levodopa levels. Reduces "off" time and dyskinesia in advanced disease. Requires daily management of the pump and tube, and carries risks of infection and tube complications.

Subcutaneous apomorphine infusion is used in some countries for continuous dopaminergic stimulation — less commonly in the U.S. MRI-guided focused ultrasound (MRgFUS) is an emerging option for tremor-dominant disease that avoids open surgery, though its role is still being defined.

All of these are highly specialized. They require evaluation at a movement disorder center and are not appropriate for all patients. For a broader picture of how chronic disease management is structured — including medication adherence strategies that apply across conditions — this how to manage type 2 diabetes reference covers the same principles from a different chronic disease.

Section 07 · Safety

Monitoring and interactions — what every patient and caregiver should know.

SAFETY · PARKINSON'S MEDICATIONS

Parkinson's medications require attention to timing, interactions, and monitoring. These checks matter.

Never stop abruptly

Abrupt discontinuation of levodopa or dopamine agonists can cause a parkinsonism-hyperpyrexia syndrome — a rare but life-threatening condition resembling neuroleptic malignant syndrome. All Parkinson's medications should be tapered under medical guidance.

Timing is critical

Levodopa absorption is affected by meals — particularly high-protein meals, which compete with levodopa for transport across the gut and blood-brain barrier. Take medications on a consistent schedule, and ask about timing relative to meals.

Drug interactions

MAO-B inhibitors interact with many antidepressants, opioids, and sympathomimetics. Antipsychotics and antiemetics (metoclopramide, prochlorperazine) can block dopamine and worsen symptoms. Every prescriber and pharmacist should have a complete medication list. A useful model for how routine interaction screening works appears in this reference on Metformin side effects, and the same principle applies to Parkinson's medications.

Impulse control

Dopamine agonists can cause compulsive gambling, shopping, eating, and hypersexuality — reported by patients and families. These are medication side effects, not character changes, and they improve when the dose is reduced or the drug is changed.

Orthostatic hypotension

Blood pressure drops when standing are common — from the disease itself and from medications. Rise slowly, hydrate, and discuss compression stockings or medication adjustments if symptoms are bothersome.

Falls prevention

Postural instability increases fall risk — particularly in later stages. Physical therapy, home safety assessment, and assistive devices matter. Exercise is one of the few interventions with evidence for slowing functional decline.

Section 08 · What to watch for

Signs that require urgent medical evaluation.

Urgent evaluation

If any of these appear in a patient with Parkinson's disease, seek immediate medical attention.

Fever, severe rigidity, confusion, and autonomic instability after stopping Parkinson's medications. Possible parkinsonism-hyperpyrexia syndrome — a medical emergency requiring ICU-level care.

New confusion, hallucinations, or severe agitation. Can be caused by medications, infection, or metabolic disturbance — requires prompt evaluation, especially in older patients.

Sudden inability to swallow, severe choking, or new-onset aspiration. Swallowing dysfunction is common in advanced PD and can lead to aspiration pneumonia — requires urgent evaluation.

Major fall with head injury. Even without symptoms, head injury in an older adult on multiple medications requires evaluation — subdural hematoma is a real risk.

Syncope, near-syncope, or a fall with loss of consciousness. Could indicate orthostatic hypotension, arrhythmia, or another cardiovascular cause — requires evaluation.

New severe pain, swelling, or redness at a DBS or PEG tube site. Could indicate infection — requires prompt evaluation and likely antibiotic treatment.

Section 09 · Access & affordability

Parkinson's medications are mostly generic — but some are expensive and the price varies.

Carbidopa/levodopa is available as a low-cost generic — often on $4 lists at major pharmacies. Dopamine agonists, MAO-B inhibitors, and COMT inhibitors are also available as generics in most cases. Extended-release formulations, patches, and device-assisted therapies are typically brand-only and expensive. DBS surgery is covered by Medicare and most commercial insurance when medically appropriate, with coverage criteria that vary by plan.

Patient assistance programs from manufacturers and foundations help with copays for newer agents. For patients on multiple chronic medications — which is common in Parkinson's, given the frequent coexistence of hypertension, diabetes, and other age-related conditions — pharmacy-level pricing differences can add up. A quick comparison before each refill can reveal meaningful savings. A reference like this one on Metformin online pharmacy shows how these comparisons work in practice, and a step-by-step guide for a first online refill is available at order Metformin online — prescription first, licensed seller second, small first order third.

Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. Parkinson's medications are time-sensitive and dosing-sensitive; anything less than a properly licensed seller is not worth the risk.

Section 10 · Questions

Five asked most often in the movement disorder clinic.

Q·01 What is Parkinson's disease? +

Parkinson's disease is a progressive neurodegenerative disorder in which dopamine-producing neurons in the substantia nigra of the brain gradually degenerate. The loss of dopamine disrupts the basal ganglia circuits that control movement, producing the characteristic motor symptoms of tremor, rigidity, slowness, and postural instability. Non-motor symptoms — sleep disruption, constipation, mood changes — are common and often appear years before the motor symptoms.

Q·02 Is levodopa still the best treatment for Parkinson's disease? +

Levodopa combined with carbidopa remains the most effective medication for the motor symptoms of Parkinson's disease, and is the standard first-line therapy for most patients. It works by replacing the missing dopamine in the brain. Long-term use is associated with motor fluctuations and dyskinesias, but these are manageable with careful dosing and additional medications.

Q·03 What are "on" and "off" periods in Parkinson's disease? +

As Parkinson's progresses and levodopa is used for years, its effect becomes less stable. "On" periods are when the medication is working and symptoms are controlled. "Off" periods are when the medication wears off and symptoms return — sometimes suddenly. Managing these fluctuations is a major focus of advanced Parkinson's care, addressed through dose adjustments, additional medications, or device-assisted therapies.

Q·04 Is deep brain stimulation safe? +

Deep brain stimulation (DBS) is a well-established surgical therapy for carefully selected patients with Parkinson's disease. It involves implanting electrodes in the brain connected to a pulse generator in the chest. DBS can significantly reduce motor fluctuations and dyskinesia, and improve quality of life, but it carries surgical risks including infection and bleeding, and requires ongoing programming and monitoring. It is not appropriate for everyone.

Q·05 Can Parkinson's disease be cured? +

There is currently no cure for Parkinson's disease. Treatment is aimed at managing symptoms, maintaining function, and improving quality of life. Research into disease-modifying therapies continues, but no treatment has been shown to slow or stop the underlying neurodegeneration. Physical therapy, exercise, and multidisciplinary care play important roles alongside medication.

◆ Sources & Verification

This reference is aligned with public clinical guidance from the International Parkinson and Movement Disorder Society (MDS), the American Academy of Neurology (AAN), the National Institute of Neurological Disorders and Stroke (NIH), and the U.S. Food and Drug Administration's BeSafeRx program. Drug-label information draws on the National Library of Medicine's DailyMed database and MedlinePlus. Pharmacy verification follows the NABP VIPPS program.

◆ Before the next refill

Parkinson's medications are time-sensitive. Prescription pricing should not be the obstacle.

Many Parkinson's medications are available as low-cost generics, and the same tablet can cost several times more at one licensed pharmacy than another. A two-minute comparison across licensed U.S. sellers is a useful habit for any patient on multiple chronic medications. Start with the current Metformin for sale comparison as a live demonstration of how wide the spread runs.

Open the price comparison